Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Factors Influencing Initial Choice Of Insulin Therapy In A Large International Non-interventional Study Of People With Type 2 Diabetes

N. Freemantle, B. Balkau, N. Danchin, E. Wang, M. Marre, G. Vespasiani, R. Kawamori, P. Home
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Aim: To use baseline characteristics of the Cardiovascular Risk Evaluation in people with type 2 Diabetes on Insulin Therapy study population to identify factors that could explain the choice of insulin therapy when beginning insulin.
This paper references
10.2337/dc06-2499
How Doctors Choose Medications to Treat Type 2 Diabetes
R. Grant (2007)
10.2337/DIACARE.29.04.06.DC05-0053
Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.
M. Peyrot (2005)
10.1016/j.diabres.2008.06.008
Study design and baseline characteristics of patients in the PRESENT study.
M. Shestakova (2008)
10.1507/ENDOCRJ.K09E-366
Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients.
K. Arai (2010)
10.1056/NEJMoa0806470
10-year follow-up of intensive glucose control in type 2 diabetes.
R. Holman (2008)
International Diabetes Federation. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: Brussels International Diabetes Federation
(2005)
10.1136/pgmj.2008.067926
New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes
W. Crasto (2009)
10.1111/j.1742-1241.2008.01917.x
The IMPROVE™ study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts
P. Valensi (2008)
10.4158/EP.13.S1.1
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus.
H. Rodbard (2007)
10.1016/S0140-6736(09)60697-8
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
K. Ray (2009)
10.1016/S0168-8227(99)00019-4
Heterogeneous relationship of early insulin response and fasting insulin level with development of non-insulin-dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity.
H. Yoshinaga (1999)
10.2337/DIACARE.27.7.1535
The burden of treatment failure in type 2 diabetes.
J. Brown (2004)
10.1007/s00125-008-1157-y
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
D. Nathan (2008)
0] 8.2 (1.6) [7.9, 8.6] 9.8 (2.0) [9.6, 9.9] 8.8 (1.7) [8
10.1016/J.CLINTHERA.2007.07.004
Importance of observational studies in clinical practice.
R. Ligthelm (2007)
10.1007/s00125-009-1470-0
Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. Turnbull (2009)



This paper is referenced by
OptiMising therapy after MetfOrMin in type 2 diabetes
R. Moore (2015)
10.1007/s00592-019-01346-1
High level of clinical inertia in insulin initiation in type 2 diabetes across Central and South-Eastern Europe: insights from SITIP study
Matthew D. Campbell (2019)
O R I G I N a L I N V E S T I G a T I O N Open Access
Ryuzo Kawamori ()
10.5114/aoms.2020.93264
Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience
Serhat Ozcelik (2020)
10.2337/dc13-3010
Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin
B. Balkau (2014)
10.1111/dom.12598
Relationship of glycaemic control and hypoglycaemic episodes to 4‐year cardiovascular outcomes in people with type 2 diabetes starting insulin
N. Freemantle (2016)
10.2174/0929867324666171009115356
Fighting type-2 diabetes: present and future perspectives.
Cai-Guo Yu (2017)
10.1016/j.diabres.2015.02.034
Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study.
B. Balkau (2015)
10.1111/jdi.12605
Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review
W. Sheu (2017)
10.1016/j.diabres.2015.01.030
Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents.
P. Home (2015)
10.1016/S1957-2557(15)30011-0
Le diabète de type 2 au stade de l’insuline : Quelle place pour les inhibiteurs de la DPP-4 ?
S. Halimi (2015)
10.1111/dom.12147
A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes
N. Freemantle (2013)
10.1111/dom.13909
Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial
H. Sone (2019)
10.2337/dci20-0038
Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin
G. Bolli (2020)
10.1111/dom.13179
Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study
P. Home (2018)
10.1507/endocrj.EJ17-0020
Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial.
H. Watada (2017)
10.1186/s13098-018-0366-x
Twice-daily insulin degludec/insulin aspart effectively improved morning and evening glucose levels and quality of life in patients previously treated with premixed insulin: an observational study
Kanta Fujimoto (2018)
10.1186/1475-2840-12-131
Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study
R. Kawamori (2013)
10.24843/UJOSSH.2017.V01.I02.P03
Influence of Patient Characteristics on The Type of Insulin Therapy Obtained by Diabetes Type 2 Outpatient in Denpasar Municipality
L. P. F. Larasanty (2017)
10.1002/dmrr.3062
Blood glucose profiles in East Asian and Caucasian injection‐naive patients with type 2 diabetes inadequately controlled on oral medication: a pooled analysis
X. Zhang (2018)
10.1002/dmrr.2816
Comparison of insulin lispro mix 25 with insulin lispro mix 50 as an insulin starter in Asian patients with type 2 diabetes: a phase 4, open‐label, randomized trial (CLASSIFY study)
H. Watada (2017)
10.1016/j.jdiacomp.2014.09.012
Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA)
M. Odawara (2015)
10.1016/j.jdiacomp.2017.03.011
Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program.
L. Ji (2017)
10.1186/s12913-016-1264-2
Utilization patterns of insulin therapy and healthcare services among Japanese insulin initiators during their first year: a descriptive analysis of administrative hospital data
S. Ikeda (2015)
10.1016/j.diabres.2017.08.016
Insulin regimens and glycemic control in different parts of Europe over 4years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study.
L. Blonde (2017)
10.1016/S1957-2557(14)70892-2
Première année de suivi des patients diabétiques de type 2 mis sous insuline en vie réelle (étude CREDIT-France)
B. Balkau (2014)
10.1007/s13300-018-0530-1
Unmet Needs in the Management of Type 2 Diabetes Mellitus Patients Starting Insulin Therapy with Basal or Premix Insulin in Routine Clinical Practice in Serbia
T. B. Beljić Živković (2018)
10.1186/s12933-016-0407-4
Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
N. Inagaki (2016)
10.1016/j.diabres.2016.04.008
Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues.
J. Gautier (2016)
Semantic Scholar Logo Some data provided by SemanticScholar